Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | RR 1 [0.27, 3.7] | 3 studies · 451 participants | Very low |
Intervention NR Number of participants with any bleeding ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of participants with clinically significant bleeding · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | 1 study · 84 participants | Very low |
Intervention NR Serious infections ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Length of hospital admission ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Hospital readmission rate ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | 3 studies · 431 participants | Very low |
Intervention NR Number of participants with any bleeding (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | RR 0.91 [0.78, 1.06] | 3 studies · 448 participants | Low |
Intervention NR Number of participants with clinically significant bleeding (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | RR 0.94 [0.74, 1.19] | 4 studies · 511 participants | Low |
Intervention NR Serious infections (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | RR 1.2 [0.93, 1.55] | 3 studies · 451 participants | Low |
Intervention NR Length of hospital admission (days) (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | 2 studies · 388 participants | Moderate |
Intervention NR Hospital readmission (0 to 3 months) · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | RR 0.89 [0.52, 1.5] | 1 study · 299 participants | Low |
Intervention NR All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | 1 study · 84 participants | Very low |
Intervention NR Quality of life ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD20 mAb maintenance therapy vs observation Overall survival · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | HR 0.94 [0.73, 1.2] | 3 studies · 1152 participants | Moderate |
Immunomodulatory drug maintenance therapy vs placebo/observation Grade 3/4 adverse events · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Rate ratio 1.82 [1.38, 2.38] | 2 studies · 400 participants | Low |
Immunomodulatory drug maintenance therapy vs placebo/observation Progression‐free survival · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | HR 0.37 [0.19, 0.73] | 3 studies · 461 participants | Moderate |
Immunomodulatory drug maintenance therapy vs placebo/observation Treatment‐related mortality · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Risk ratio 1.22 [0.35, 4.29] | 3 studies · 458 participants | Low |
Immunomodulatory drug maintenance therapy vs placebo/observation Treatment discontinuation · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Risk ratio 0.71 [0.47, 1.05] | 2 studies · 400 participants | Very low |
Immunomodulatory drug maintenance therapy vs placebo/observation All adverse events · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Rate ratio 1.41 [1.28, 1.54] | 3 studies · 458 participants | Moderate |
Anti‐CD52 mAb maintenance therapy vs observation Overall survival – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation Health‐related quality of life – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation Grade 3/4 adverse events – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation Progression‐free survival · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | HR 0.55 [0.32, 0.95] | 1 study · 21 participants | Very low |
Anti‐CD52 mAb maintenance therapy vs observation Treatment‐related mortality – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD20 mAb maintenance therapy vs observation Health‐related quality of life · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | 1 study · 480 participants | Low |
Anti‐CD52 mAb maintenance therapy vs observation Treatment discontinuation – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation All adverse events – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD20 mAb maintenance therapy vs observation Grade 3/4 adverse events · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Rate ratio 1.34 [1.06, 1.71] | 5 studies · 1284 participants | Low |
Anti‐CD20 mAb maintenance therapy vs observation Progression‐free survival · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | HR 0.61 [0.5, 0.73] | 5 studies · 1255 participants | Moderate |
Anti‐CD20 mAb maintenance therapy vs observation Treatment‐related mortality · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Risk ratio 0.82 [0.39, 1.71] | 4 studies · 1189 participants | Low |
Anti‐CD20 mAb maintenance therapy vs observation Treatment discontinuation · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Risk ratio 0.93 [0.72, 1.2] | 6 studies · 1321 participants | Low |
Anti‐CD20 mAb maintenance therapy vs observation All adverse events · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Rate ratio 1.23 [1.03, 1.47] | 6 studies · 1321 participants | Low |
Immunomodulatory drug maintenance therapy vs placebo/observation Overall survival · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | HR 0.91 [0.61, 1.35] | 3 studies · 461 participants | Moderate |
Immunomodulatory drug maintenance therapy vs placebo/observation Health‐related quality of life – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy Overall survival (at 36 months) · people with newly diagnosed multiple myeloma ineligible for transplant Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed… (2024) · Cochrane | HR 0.64 [0.53, 0.76] | 2 studies · 1443 participants | Moderate |
Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy Progression‐free survival (at 24 months) · people with newly diagnosed multiple myeloma ineligible for transplant Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed… (2024) · Cochrane | HR 0.48 [0.39, 0.58] | 3 studies · 1663 participants | Moderate |
Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy Quality of life: EORTC 12 monthScale from: 0 to 100 · people with newly diagnosed multiple myeloma ineligible for transplant Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed… (2024) · Cochrane | no estimate extracted | 3 studies · 1096 participants | Low |
Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy On‐study mortality (longest available · people with newly diagnosed multiple myeloma ineligible for transplant Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed… (2024) · Cochrane | Risk Ratio 0.72 [0.62, 0.83] | 3 studies · 1644 participants | Moderate |
Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy Serious adverse events (longest available · people with newly diagnosed multiple myeloma ineligible for transplant Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed… (2024) · Cochrane | Risk Ratio 1.18 [1.02, 1.37] | 3 studies · 1644 participants | Moderate |
Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy Adverse events (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed… (2024) · Cochrane | Risk Ratio 1.01 [0.99, 1.02] | 3 studies · 1644 participants | Moderate |
Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy Adverse events: infections (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed… (2024) · Cochrane | Risk Ratio 1.52 [1.3, 1.78] | 3 studies · 1644 participants | Moderate |
Intervention NR Overall survival (at 36 months) · patients after allogeneic stem cell or bone marrow transplantation Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem… (2023) · Cochrane | HR 0.93 [0.77, 1.13] | 9 studies · 1249 participants | Moderate |
Intervention NR Acute GVHD II to IV (90 days) · patients after allogeneic stem cell or bone marrow transplantation Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem… (2023) · Cochrane | RR 0.68 [0.6, 0.79] | 10 studies · 1413 participants | High |
Intervention NR Overall Chronic GVHD (up to 36 months) · patients after allogeneic stem cell or bone marrow transplantation Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem… (2023) · Cochrane | RR 0.53 [0.45, 0.61] | 8 studies · 1273 participants | High |
Intervention NR Incidence of relapse (up to 36 months) · patients after allogeneic stem cell or bone marrow transplantation Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem… (2023) · Cochrane | RR 1.21 [0.99, 1.49] | 8 studies · 1315 participants | Moderate |
Intervention NR Non‐relapse mortality (at 36 months) · patients after allogeneic stem cell or bone marrow transplantation Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem… (2023) · Cochrane | HR 0.86 [0.67, 1.11] | 9 studies · 1370 participants | Moderate |
Intervention NR Graft failure (during study) · patients after allogeneic stem cell or bone marrow transplantation Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem… (2023) · Cochrane | RR 1.55 [0.54, 4.44] | 8 studies · 1240 participants | Low |
Intervention NR Adverse Events (during study) · patients after allogeneic stem cell or bone marrow transplantation Polyclonal anti‐thymocyte globulins for the prophylaxis of graft‐versus‐host disease after allogeneic stem… (2023) · Cochrane | no estimate extracted | 4 studies · 543 participants | Moderate |
Summary of findings table ‐ Convalescent plasma vs placebo or standard care alone All‐cause mortality at up to day 28 ‐ total · individualswith moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | RR 0.98 [0.92, 1.03] | 21 studies · 19021 participants | High |